13th European ISSX Meeting Program
description
Transcript of 13th European ISSX Meeting Program
Welcome to Glasgow!
Dear Colleagues and Friends,
On behalf of the International Society for the Study of Xenobiotics (ISSX), it is with pleasure that we welcome you to the 13th European ISSX Meeting. The Meeting Organising Committee, symposia chairs, and speakers have carefully designed a programme to address key research topics including: PBPK Modeling, Stem Cell Technology Developments and their Application to Drug Metabolism and Drug Safety, the Role of Drug Transporters, Epigenomics in Drug Metabolism and Disease, Mass Spectrometry of Small Molecules, and much more.
The meeting begins with four short courses on mass spectrometry, stem cell derived tissues, and pharmacokinetic modeling. These courses are followed by an opening keynote lecture presented by Professor Sir Philip Cohen of the University of Dundee and our Opening Welcome Reception with exhibitors. The meeting additionally features twelve scientific symposia and additional plenary sessions. The European Scientific Achievement Award and the European New Investigator Award in Honor of Karl J. Netter will be presented to this year's award winners on Wednesday, June 24 at 16:15. The abstract poster sessions will cover a wide range of contemporary research topics and winners of the ISSX Poster Awards Competition will be announced on Thursday, June 25 at 12:30. Complementing the meeting, top suppliers to the scientific community will present their products and services during the meeting exhibition hours each day.
The premier social event for this meeting is a dinner and ceilidh at the Glasgow Old Fruitmarket on Wednesday, June 24 at 18:30. This unique setting is the perfect backdrop to enjoy a meal and entertainment with friends and colleagues. Tickets may still be available. Please enquire at the registration counter in the Level 2 Foyer.
When not attending the sessions, we hope you will explore the charming and vibrant city of Glasgow. There is a diverse array of cultural and entertainment options available along with an excellent dining scene. Supported by a great transportation network, meeting attendees and accompanying guests can take in all that this unique and beautiful city has to offer.
Welcome and enjoy the meeting!
Sincerely,
Roland Wolf, PhD, OBE and Ann Daly, PhD University of Dundee Newcastle University 13th European ISSX Meeting Co-Chairs
Table of Contents
Schedule Overview
General Information
Scientific Program
Poster Information
Exhibitor Directory
2
8 – 9
10 – 14
15 – 16
19 – 22
Inside Front Cover Welcome from 13th European ISSX Meeting Co-Chairs, Ann Daly and Roland Wolf
2 Schedule Overview
3 13th European ISSX Meeting Committees
4 Upcoming ISSX Meetings
5 ISSX Leadership and Staff
6 – 7 European ISSX Awards
8 – 9 General Information and
Glasgow City Map
10 – 14 Scientific Program
15 – 16 Poster Information
17 Industry-Sponsored Symposium and ISSX Sponsors
18 ISSX Meeting Dinner and Ceilidh
19 – 22 Exhibitor Directory
22 – 24 Notes Pages
Inside Back Cover Technology and Innovation Centre Floor Plan
Schedule Overview
Monday, June 22, 2015 08:00 – 19:00 LEVEL 2 FOYER Meeting Registration Open
13:00 – 17:00 LEVELS 2 and 3 FOYER Exhibitor Set-Up
09:00 – 12:30 AUDITORIUMS A and B/C Concurrent Morning Short Courses 1 and 2*
12:30 – 13:30 CONFERENCE ROOMS 6 and 7 Lunch for All Short Course Registrants
13:30 – 17:00 AUDITORIUMS A and B/C Concurrent Afternoon Short Courses 3 and 4*
17:45 – 18:00 AUDITORIUM A/B/C Opening Session
18:00 – 18:45 AUDITORIUM A/B/C Opening Keynote Lecture
18:45 – 20:45 LEVELS 2 and 3 FOYER Opening Welcome Reception / Meet the Exhibitors
Tuesday, June 23, 2015 07:30 – 17:00 LEVEL 2 FOYER Meeting Registration Open
07:30 – 09:00 LEVEL 2 FOYER Finalist Awards Poster Set-Up
07:30 – 09:00 LEVEL 3 FOYER and ROOM 4/5 General Poster Set-Up
07:45 – 08:45 AUDITORIUM A Industry-Sponsored Symposium: Quotient Bioresearch
09:00 – 12:00 AUDITORIUMS A and B/C Parallel Symposia 1 and 2
10:30 – 11:00 LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters
12:00 – 13:30 LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch / View Posters
12:00 – 13:00 LEVEL 2 FOYER Finalist Awards Posters A1 through A6 Presented
12:30 – 13:30 LEVEL 3 FOYER and ROOM 4/5 General Posters P1 through P85 Presented
13:30 – 15:30 AUDITORIUMS A and B/C Parallel Symposia 3 and 4
15:30 – 16:00 LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters
16:00 – 18:30 AUDITORIUMS A and B/C Parallel Symposia 5 and 6
18:30 – 19:30 GLASGOW CITY CHAMBERS Civic Reception*
19:30 – 22:00 WAXY O’CONNOR’S New Investigators Reception*
Wednesday, June 24, 2015 08:00 – 17:00 LEVEL 2 FOYER Meeting Registration Open
09:00 – 12:00 AUDITORIUMS A and B/C Parallel Symposia 7 and 8
10:30 – 11:00 LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters
12:00 – 13:30 LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch / View Posters
12:00 – 13:00 LEVEL 2 FOYER Finalist Awards Posters A7 through A12 Presented
12:30 – 13:30 LEVEL 3 FOYER and ROOM 4/5 General Posters P86 through P166 Presented
13:30 – 15:30 AUDITORIUMS A and B/C Parallel Symposia 9 and 10
15:30 – 16:15 LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters
16:15 – 17:30 AUDITORIUM A/B/C Presentation of ISSX Awards
18:30 – 22:00 OLD FRUITMARKET Meeting Dinner and Ceilidh*
Thursday, June 25, 2015 08:00 – 17:00 LEVEL 2 FOYER Meeting Registration Open
09:00 – 11:30 AUDITORIUMS A and B/C Parallel Symposia 11 and 12
11:30 – 12:30 LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch / View Posters
12:30 – 13:00 AUDITORIUM A/B/C Presentation of ISSX Poster Awards
13:00 – 15:00 AUDITORIUM A/B/C Plenary Session
15:00 – 15:45 AUDITORIUM A/B/C Closing Plenary Lecture
15:45 – 16:00 AUDITORIUM A/B/C Closing Remarks
*These events require a ticket. If you are interested in attending, please inquire at the registration counter.
2
13th European ISSX Meeting Committees
Meeting Organising Committee Chairs
Ann Daly, PhD, Newcastle University
Roland Wolf, PhD, University of Dundee
Meeting Organising Committee
John Hayes, PhD, University of Dundee
Brian Houston, PhD, University of Manchester
Neil Kitteringham, PhD, University of Liverpool
Michael McMahon, PhD, University of Dundee
Richard Meehan, PhD, University of Edinburgh
Munir Pirmohamed, PhD, University of Liverpool
Colin Suckling, PhD, University of Strathclyde
Geoff Tucker, PhD, University of Sheffield and Simcyp Limited (a Certara Company)
Michael Voice, PhD, Cypex, Ltd.
Heather Wallace, PhD, University of Aberdeen
Matt Wright, PhD, Newcastle University
Abstract Review Committee
Thomas Baillie, PhD, University of Washington
John Hayes, PhD, University of Dundee
Brian Houston, PhD, University of Manchester
Neil Kitteringham, PhD, University of Liverpool
Michael McMahon, PhD, University of Dundee
Richard Meehan, PhD, University of Edinburgh
Munir Pirmohamed, PhD, University of Liverpool
Colin Suckling, PhD, University of Strathclyde
Geoff Tucker, PhD, University of Sheffield and Simcyp Limited (a Certara Company)
Heather Wallace, PhD, University of Aberdeen
Matt Wright, PhD, Newcastle University
Poster Awards Review Committee
Thomas Baillie, PhD, University of Washington
John Hayes, PhD, University of Dundee
Brian Houston, PhD, University of Manchester
Michael McMahon, PhD, University of Dundee
Edward Morgan, PhD, Emory University
Heather Wallace, PhD, University of Aberdeen
3
Upcoming ISSX Meetings
20th North American ISSX Meeting
October 18 – 22, 2015 Hilton Orlando Bonnet Creek Orlando, Florida, USA Meeting Chairs: Hartmut Derendorf, PhD and Stephan Schmidt, PhD www.issx.org/20NA
11th International ISSX Meeting
June 12 – 16, 2016 Busan Exhibition and Convention Center Busan, Korea Meeting Chair: Jae-Gook Shin, MD, PhD www.issxbusan2016.org
21st North American ISSX Meeting
September 24 – 28, 2017 Rhode Island Convention Center Providence, Rhode Island, USA Meeting Chair: Jashvant Unadkat, PhD
ISSX meetings bring together individuals involved in drug/xenobiotic research in diverse fields including
basic and clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology,
biochemistry, medicinal chemistry, molecular and structural biology, and genetics. Everyone studying or
working in the fields of toxicology, pharmacology, molecular biology, and other areas related to the study
of xenobiotics learn and benefit from attending ISSX meetings. The many benefits of participating in ISSX
meetings include:
• Participate in your choice of multiple short courses designed to deliver a broad-based educational experience.
• Attend outstanding lectures delivered by leading scientists who will share the latest developments in their areas of research.
• Gain recognition and feedback on your research by submitting an abstract and presenting a poster.
• Avail yourself of the many opportunities for substantive conversation and networking with scientists worldwide.
• Meet with our exhibitors who will showcase products and services that could be helpful solutions for you in your research and development.
• Compete for prizes in the student and postdoc poster competition. • Engage in informal social interactions with fellow researchers. • Enjoy the meeting location. ISSX aims to hold meetings in desirable locations that provide
opportunities for attendees to explore cultures and have fun.
Make plans to attend and encourage your colleagues to participate in our upcoming meetings.
4
ISSX Leadership and Staff
President
John Miners Department of Clinical Pharmacology Flinders University School of Medicine Adelaide, Australia
President-Elect/Secretary
Geoff Tucker University of Sheffield and Simcyp Limited (a Certara Company) Sheffield, United Kingdom
Treasurer
Andrew Parkinson XPD Consulting Shawnee, Kansas, USA
Treasurer-Elect
James Halpert University of Connecticut Storrs, Connecticut, USA
Members of Council
Thomas Baillie University of Washington School of Pharmacy Seattle, Washington, USA
Maria Almira Correia University of California San Francisco, California, USA
Ann Daly Newcastle University Institute of Cellular Medicine Newcastle Upon Tyne, United Kingdom
Natalie Hosea Pfizer, Incorporated Cambridge, Massachusetts, USA
Takashi Izumi Daiichi-Sankyo Company, Limited Shinagawa-ku, Tokyo, Japan
Lawrence Marnett Vanderbilt University School of Medicine Nashville, Tennessee, USA
Jasminder Sahi Sanofi Pudong, Shanghai, China
Allan Rettie, Chair, Scientific Affairs Committee Ex-Officio to Council University of Washington Department of Medicinal Chemistry Seattle, Washington, USA
ISSX Staff
Steven Kemp, CAE Executive Director
Zoë Fuller Program Manager
Sarah Langan Program Coordinator
Diana DiAntonio Sr. Program Associate
Ashley Pencak Meeting Manager
Steve Rabeor Exhibits and Sponsorship Sales Manager
Brittany Jackson Exhibits Coordinator
Sunny Patel Accountant
5
European ISSX Awards
European Scientific Achievement Award Presented to James Brian Houston
The European Scientific Achievement Award is presented to an ISSX member who has
made major scientific contributions to the field within the European region. The
purpose of this award is to recognize meritorious contributions by senior or mid-career
scientists that have had a major impact on research in the field. The 2015 recipient is
James Brian Houston, PhD, Professor of Drug Metabolism and Pharmacokinetics, at the
University of Manchester.
Professor Houston obtained his BSc, PhD, and DSc from the Universities of London
(Queen Mary College), Surrey and Manchester, respectively. He is Professor of Drug Metabolism &
Pharmacokinetics and Director of the Centre for Applied Pharmacokinetic Research at the University of
Manchester. His research interests are in quantitative drug metabolism and pharmacokinetics. He has
provided a lead in the development, evaluation, and implementation of in vitro and in silico approaches to
prediction of human pharmacokinetics promoting the movement away from empirical towards
mechanism-based approaches to prediction. Much of his work is carried out in collaboration with various
pharmaceutical companies. He has supervised more than 50 graduate students. His research publications
in the area of drug metabolite kinetics in vivo and in vitro exceed 200 and are highly cited (with five citation
classics). He has authored/coauthored more than 20 reviews and received more than 100 invitations to
present at national and international meetings. He is a member of the editorial boards of several journals
including Journal of Pharmacology & Therapeutics (1999-2002), Drug Metabolism & Disposition (2002-on)
and Xenobiotica (2008-on), and has served as a director on the governing board of ISSX.
The research by Professor Houston has been highly influential by informing regulatory practice in Europe
and the USA and by establishing and optimizing industrial practices related to drug development,
particularly those related to drug-drug interactions. Professor Houston’s work has also reduced the usage
of animals in research via in vitro – in vivo extrapolation of clearance values as well as other
pharmacokinetic attributes of drug molecules. These techniques have pioneered the movement away from
traditional, essentially empirical approaches towards mechanism-based prediction strategies to avoid the
previously common failure of drugs due to poor PK properties, and to increase the efficiency of clinical
trials. The methodologies have accelerated the discovery and development of better and safer drugs and
have dictated the evolution of best practices recommended by the regulators and have been subsequently
widely-adopted across the pharmaceutical industry.
To recognize and celebrate his substantial contributions to the field of xenobiotic disposition including his
service in the leadership of ISSX and other scientific societies, ISSX proudly awards James Brian Houston
the 2015 European Scientific Achievement Award.
Award Presentation and Lecture: Wednesday, June 24, 2015 | 16:15 – 17:30 | AUDITORIUM A/B/C
6
European ISSX Awards
European New Investigator Award in Honor of Karl J. Netter Presented to Daniel J. Antoine
The 2015 European New Investigator Award in Honor of Karl J. Netter is presented to
an ISSX member who has made significant contributions to the field during their early
career years. The purpose of this award is to encourage and recognize a developing
scientist who is active in the field in Europe.
Dr. Daniel J. Antoine’s research focus is on the development of novel biomarkers of
drug-induced liver injury that can be used to investigate the mechanistic basis of
adverse reactions to drugs as well as provide perspectives on risk-benefit in man.
Recognition for his research has come in the form of the award of a number of academic prizes (British
Toxicology Society Early Career Investigator Award 2013), honorary research fellowships (Harvard Medical
School, USA), a number of invited speaker invitations at international meetings as well as gaining
independent research grant funding from research councils and the pharmaceutical industry.
Dr. Antoine has developed a number of national and international collaborations that have resulted in a
high number of publications for his stage in his career, many of which as first, senior or corresponding
author. Further evidence of Dr. Antoine’s desire to further advance the field of drug safety science is
illustrated by his membership and recent election to a number of committees such as Co-Chair of the
Toxicology Affinity Group for the British Pharmacological Society (2014), Councilor for the IUPHAR Drug
Metabolism and Transporter Executive Board (2014) and the IVTS committee (as Treasurer 2010 –2012).
Dr. Antoine additionally serves as an editorial board member for the journals Pharmacology Research &
Perspective and Biomarkers.
Dr. Antoine has also developed a number of independent collaborations with internationally-recognized
institutions, namely with the Harvard Medical School and the Karolinska Institutet, which has resulted in
the award of honorary research fellowships at these prestigious institutions. In addition to his commitment
to high-quality scientific research, Dr. Antoine is also committed to the teaching and training of future
pharmacological scientists at the University of Liverpool and elsewhere through Masters and Honors
courses.
In recognition of his significant scientific contributions early in his career as well as future strong potential
in the field of foreign compound metabolism and disposition, ISSX proudly bestows the 2015 European
New Investigator Award in Honor of Karl J. Netter to Daniel J. Antoine.
Award Presentation and Lecture: Wednesday, June 24, 2015 | 16:15 – 17:30 | AUDITORIUM A/B/C
CALL FOR NOMINATIONS: 20th NORTH AMERICAN ISSX MEETING AWARDS
www.issx.org/awards/nominations
The 2015 North American Scientific Achievement Award in Honor of Ronald Estabrook, Sponsored by XenoTech, and the 2015 North American New Investigator Award in Honor of James R. Gillette, will be presented at the
20th North American ISSX Meeting in October 2015 in Orlando, Florida.
The awards will include travel support to the meeting. Nominate a deserving member today!
7
General Information
Meeting Venue University of Strathclyde The Technology and Innovation Centre 99 George Street Glasgow G1 1RD United Kingdom Telephone: +44 141 444 7000
Abstracts
Meeting abstracts are available for review in the abstract book provided to attendees at check-in and online at www.issx.org/onlineabstracts.
Information for Invited Speakers An audio-visual technician will be available to assist speakers with loading their presentations. Speakers should bring their presentations on a USB flash drive to their assigned session room no less than 30 minutes prior to the beginning of the session.
ISSX Awards Session The ISSX Awards Session will be held at 16:15 on Wednesday, June 24 in Auditorium A/B/C. The Society’s highest awards presented in the European region will be bestowed to the award winners who will then deliver their award lectures. We encourage all meeting attendees to be present at this important session and to show their support of this year’s celebrated awardees.
Name Badges Name badges are required for admission to the meeting sessions, the exhibit space, and social functions. Badges help facilitate networking and communication with your fellow attendees. If you lose your name badge please visit the registration counter for assistance.
Opening Welcome Reception Fully-registered attendees and registered guests are invited to attend the Opening Welcome Reception on Monday, June 22 from 18:45 – 20:45 in the Level 2 and 3 Foyers. Our exhibitors will be on-hand to meet you and share information about their latest products and services. Hors d’oeuvres will be offered and each attendee will receive one complimentary beverage ticket.
Admission to the Opening Welcome Reception is included in the full-meeting registration fee. Attendees will need their name badges in order to be admitted. Unregistered guests or single-day registrants may purchase an admission ticket for £30 for the reception at the meeting registration counter.
Premier Social Event: Meeting Dinner and Ceilidh Tickets may still be available for this special dinner on Wednesday, June 24 from 18:30 – 22:00.
Join friends and colleagues at the premier social event of the meeting at the Old Fruitmarket of Glasgow which has kept all of its period charm, including its lofty vaulted roof, cast iron columns and balcony, and slender Victorian architecture. Attendees will enjoy a delicious buffet dinner, drinks, and a ceilidh.
The word ceilidh (kay-lee) is derived from the Gaelic word for "gathering" or "party". These days when people think of a ceilidh, they think of a fun-filled night of dancing, good music, and great company!
Wi-Fi Access Complimentary Wi-Fi is available throughout the Technology and Innovation Centre. Access information is available at the registration counter.
8
General Information
Poster Awards Competition and Poster Awards Presentation The awards for best graduate/predoctoral and postdoctoral poster presentations will be held at 12:30 on Thursday, June 25 in Auditorium A/B/C. Meeting attendees may view the twelve finalist poster presentations which will be located in the Level 2 Foyer throughout the meeting.
New Investigators Reception All graduate and postgraduate students as well as postdoctoral scientists still in training who are fully-registered for this meeting are cordially invited to attend a special networking reception on Tuesday, June 23 from 19:30 – 22:00 at Waxy O’Connor’s, located at 44 West George Street. Attendees will receive one drink ticket and may purchase additional drinks with cash. Be sure to attend this event to make new friends and learn about the research interests of your peers.
Meeting Registration Hours Exhibit Hours Monday, June 22 | 08:00 – 19:00 Monday, June 22 | 18:45 – 20:45
Tuesday, June 23 | 07:30 – 17:00 Tuesday, June 23 | 10:30 – 16:00
Wednesday, June 24 | 08:00 – 17:00 Wednesday, June 24 | 10:30 – 16:15
Thursday, June 25 | 08:00 – 17:00 Thursday, June 25 | 11:30 – 12:30
Glasgow City Map
Map data ©2015 Google
9
Scientific Program
Monday, June 22, 2015 08:00 – 19:00 | LEVEL 2 FOYER
Meeting Registration Open
09:00 – 12:30 | AUDITORIUM A
Short Course 1: Mass Spectrometry in Drug Metabolism Studies Co-Chairs: Ian Wilson, Imperial College, London, United Kingdom and Neil Kitteringham, University of Liverpool, Liverpool, United Kingdom
09:00 – 09:45 | SC1.1. LC-MS IN METABOLITE IDENTIFICATION IN HIGH THROUGHPUT DRUG DISCOVERY Anthony Dickie, Evotec (UK) Ltd., Abingdon, United Kingdom
09:45 – 10:30 | SC1.2. DETECTING AND IDENTIFYING REACTIVE METABOLITES Sara Amberntsson, AstraZeneca, Mölndal, Sweden
10:30 – 11:00 | Refreshment Break
11:00 – 11:45 | SC1.3. THE USE OF LC-MS FOR COMPREHENSIVE METABOLITE CHARACTERISATION AND IDENTIFICATION Russell Mortishire-Smith, Waters Corporation, Wilmslow, United Kingdom
11:45 – 12:30 | SC1.4. TIPS, TRICKS AND LC-ICPMS FOR METABOLITE DETECTION AND IDENTIFICATION Ian Wilson, Imperial College, London, United Kingdom
09:00 – 12:30 | AUDITORIUM B/C Short Course 2: Stem Cell Derived Tissues in Toxicology Co-Chairs: Chris Goldring, University of Liverpool, Liverpool, United Kingdom and Matt Wright, Newcastle University, Newcastle upon Tyne, United Kingdom
09:00 – 09:45 | SC2.1. THE APPLICATION OF STEM CELLS IN TOXICOLOGY: WHAT DO WE NEED AND WHY DO WE NEED THEM? Chris Goldring, University of Liverpool, Liverpool, United Kingdom
09:45 – 10:30 | SC2.2. DERIVATION OF CARDIOMYCYTES STEM CELLS AND TOXICITY TESTING Chris Denning, University of Nottingham, Nottingham, United Kingdom
10:30 – 11:00 | Refreshment Break
11:00 – 11:45 | SC2.3. STEM CELL-DERIVED RENAL CELLS AND SAFETY ASSESSMENT Daniele Zink, Institute of Bioengineering and Nanotechnology, Singapore
11:45 – 12:30 | SC2.4. HEPATOCYTE STEM CELLS IN TOXICITY TESTING Matt Wright, Newcastle University, Newcastle upon Tyne, United Kingdom
12:30 – 13:30 | LEVEL 3 CONFERENCE ROOMS 6 and 7 Lunch for Short Course Registrants
13:30 – 17:00 | AUDITORIUM A Short Course 3: Physiologically-based Pharmacokinetic Modelling Co-Chairs: Geoff Tucker, University of Sheffield and Simcyp Limited (a Certara Company), Sheffield, United Kingdom and Brian Houston, University of Manchester, Manchester, United Kingdom
13:30 – 14:15 | SC3.1. USE OF PBPK MODELLING FOR FIRST IN HUMAN DOSE PREDICTIONS - INCORPORATION OF UNCERTAINTY IN EXPERIMENTAL DATA AND IN VITRO IN VIVO EXTRAPOLATION STRATEGIES Michael Gertz, F. Hoffmann-La Roche, Basel, Switzerland
14:15 – 15:00 | SC3.2. PBPK CASE STUDIES Karen Rowland-Yeo, Simcyp Limited (a Certara Company), Waterford, Massachusetts, USA
15:00 – 15:30 | Refreshment Break
15:30 – 16:15 | SC3.3. PAEDIATRIC PBPK MODELLING Kay Ogungbero, The University of Manchester, Manchester, United Kingdom
16:15 – 17:00 | SC3.4. A EUROPEAN REGULATORY PERSPECTIVE ON PBPK MODELLING Susan Cole, MHRA, London, United Kingdom
13:30 – 17:00 | AUDITORIUM B/C Short Course 4: New Horizons in Mass Spectrometry Co-Chairs: Andy Pitt, Aston University, Birmingham, United Kingdom and Neil Kitteringham, University of Liverpool, Liverpool, United Kingdom
13:30 – 14:15 | SC4.1. NEW APPLICATIONS OF PROTEOMICS IN BIOMEDICAL RESEARCH Andy Pitt, Aston University, Birmingham, United Kingdom
14:15 – 15:00 | SC4.2. IMAGING FOR XENOBIOTICS AND METABOLITES Robert Bradshaw, Sheffield Hallam University, Sheffield, United Kingdom
15:00 – 15:30 | Refreshment Break
15:30 – 16:15 | SC4.3. DATA INDEPENDENT ACQUISITION: A NEW ERA FOR QUANTITATIVE PROTEOMICS? Rosalind Jenkins, University of Liverpool, Liverpool, United Kingdom
16:15 – 17:00 | SC4.4. MAKING SENSE OF THE DATA: HOW TO HANDLE LARGE PROTEOMIC AND METABOLOMICS DATASETS Karl Burgess, University of Glasgow, Glasgow, United Kingdom
17:45 – 18:00 | AUDITORIUM A/B/C Opening Session John Miners, President, International Society for the Study of Xenobiotics Ann Daly and Roland Wolf, Co-Chairs, 13th European ISSX Meeting
18:00 – 18:45 | AUDITORIUM A/B/C Opening Keynote Lecture S1. PROTEIN KINASE INHIBITORS: MAJOR DRUGS OF THE 21ST CENTURY
Professor Sir Philip Cohen, University of Dundee, Dundee, United Kingdom
10
Scientific Program 18:45 – 20:45 | LEVELS 2 and 3 FOYERS Opening Welcome Reception / Meet the Exhibitors
Tuesday, June 23, 2015
07:30 – 17:00 | LEVEL 2 FOYER
Meeting Registration Open
07:45 – 08:45 | AUDITORIUM A Industry-Sponsored Symposium: Biopharmaceuticals: Natural Products or Xenobiotic, Friend or Foe? Andrew McEwen, Chief Scientist, Quotient Bioresearch, Ltd.
09:00 – 12:00 | AUDITORIUM A Parallel Symposium 1: Recent Developments in Stem Cell Technology and its Application to Drug Metabolism and Drug Safety Testing Co-Chairs: David Hay, University of Edinburgh, Edinburgh, United Kingdom and Ludovic Vallier, Wellcome Trust - MRC Stem Cell Institute, Cambridge, United Kingdom
09:00 – 09:30 | S2. PLURIPOTENT STEM CELL HEPATOCYTES AND TISSUE ENGINEERING David Hay, University of Edinburgh, Edinburgh, United Kingdom
09:30 – 10:00 | S3. PLURIPOTENT STEM CELL HEPATOCYTES AND CHOLANGIOCYTE MODELS Ludovic Vallier, Wellcome Trust - MRC Stem Cell Institute, Cambridge, United Kingdom
10:00 – 10:30 | S4. RECENT ADVANCES IN DERIVING HEPATOCYTE LIKE CELLS FROM INDUCED PLURIPOTENT STEM CELLS IN DRUG METABOLISM AND TOXICITY STUDIES Tommy B. Andersson, AstraZeneca, Mölndal, Sweden
10:30 – 11:00 | Refreshment Break
11:00 – 11:30 | S5. ANIMAL MODELS Stephen Strom, Karolinska Institutet, Stockholm, Sweden
11:30 – 11:45 | P84. REDUCING HUMAN DRUG OVERDOSE USING MICRORNAS Dagmara Szkolnicka, University of Edinburgh, Edinburgh, United Kingdom
11:45 – 12:00 | P18. EFFECT OF DONOR VARIABILITY AND CULTURE CONDITIONS ON PHASE II ACTIVITY IN HUMAN HEPATOCYTES Shalenie P. den Braver-Sewradj, VU University Amsterdam, Amsterdam, The Netherlands
09:00 – 12:00 | AUDITORIUM B/C Parallel Symposium 2: Expanding the Boundaries of PKPD Modelling Co-Chairs: Geoff Tucker, University of Sheffield and Simcyp Limited (a Certara Company), Sheffield, United Kingdom and Brian Houston, University of Manchester, Manchester, United Kingdom
09:00 – 09:30 | S6. SYSTEMS PHARMACOLOGY Meindert Danhof, Leiden University, Leiden, The Netherlands
09:30 – 10:00 | S7. MODELLING IN TOXICITY Oscar Della Pasqua, GlaxoSmithKline, Uxbridge, United Kingdom
10:00 – 10:30 | S8. INCORPORATING TRANSPORTER KINETICS INTO PBPK MODELS Alexandra Galetin, University of Manchester, Manchester, United Kingdom
10:30 – 11:00 | Refreshment Break
11:00 – 11:30 | S9. PBPK MODELLING OF mABs Linzhong Li, Simcyp Limited (a Certara Company), Sheffield, United Kingdom
11:30 – 11:45 | P164. SHOULD TOTAL PLASMA DRUG CONCENTRATION BE USED TO PREDICT TRANSPORTER MEDIATED DRUG-DRUG INTERACTIONS FOR HIGHLY PROTEIN BOUND DRUGS? Mark Warren, Optivia Biotechnology Inc., Menlo Park, California, USA
11:45 – 12:00 | P2. SIMULATION STUDY ON CONTRIBUTIONS OF MEMBRANE PERMEABILITY, METABOLIC CLEARANCE, AND EFFLUX TRANSPORT BY P-GLYCOPROTEIN TO INTESTINAL AVAILABILITY USING TRANSLOCATION MODEL Hirotaka Ando, Kyorin Pharmaceutical Co., Ltd., Tokyo, Japan
12:00 – 13:30 | LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch
12:00 – 13:00 | LEVEL 2 FOYER Graduate/Predoctoral Poster Finalist Poster Presentations A1 – A6 Poster Presentations
12:30 – 13:30 | LEVEL 3 FOYER and ROOM 4/5 Poster Session 1: Analytical – Hepatocytes
P1 – P85 Poster Presentations
12:30 – 13:00 | Odd Numbered Posters
13:00 – 13:30 | Even Numbered Posters
13:30 – 15:30 | AUDITORIUM A Parallel Symposium 3: Systems Toxicology Co-Chairs: Paul Watkins, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA and Bob van de Water, Leiden University, Leiden, The Netherlands
13:30 – 14:00 | S10. SYSTEMS MICROSCOPY TO UNRAVEL THE WIRING OF TOXICITY PATHWAYS IN DRUG-INDUCED LIVER INJURY Bob van de Water, Leiden University, Leiden, The Netherlands
14:00 – 14:30 | S11. A QUANTITATIVE SYSTEMS BIOLOGY ANALYSIS OF SIGNAL TRANSDUCTION NETWORKS UNDERLYING DILI Ursula Klingmueller, German Cancer Research Center, Heidelberg, Germany
14:30 – 15:00 | S12. SYSTEMS MODELING APPROACHES TO PREDICT IDIOSYNCRATIC DILI Paul Watkins, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, USA
15:00 – 15:30 | S13. INTEGRATION OF QSAR AND PK-PD MODELLING IN CARDIAC DRUG SAFETY ASSESSMENT Sebastian Polak, Simcyp Limited (a Certara Company), Sheffield, United Kingdom
11
Scientific Program 13:30 – 15:30 | AUDITORIUM B/C Parallel Symposium 4: Clinical Implementation of Pharmacogenomics Co-Chairs: Ann Daly, Newcastle University, Newcastle upon Tyne, United Kingdom and Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
13:30 – 14:00 | S14. PHARMACOGENOMIC APPROACHES TO TREATMENT OF CYSTIC FIBROSIS Margarida Amaral, Faculty of Sciences of the University of Lisbon, Lisbon, Portugal
14:00 – 14:30 | S15. IMPLEMENTATION OF PHARMACOGENOMICS IN CLINICAL PRACTICE-FOCUS ON EVIDENCE-BASED MEDICINE AND COST-EFFECTIVENESS Munir Pirmohamed, University of Liverpool, Liverpool, United Kingdom
14:30 – 15:00 | S16. IMPORTANCE OF DRUG TRANSPORTER POLYMORPHISMS AND SCOPE FOR CLINICAL IMPLEMENTATION Matthias Schwab, Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
15:00 – 15:30 | S17. APPLICATION OF PHARMACOGENOMICS IN DRUG DEVELOPMENT Martin Armstrong, UCB, Brussels, Belgium
15:30 – 16:00 | LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters
16:00 – 18:30 | AUDITORIUM A Parallel Symposium 5: Role of Drug Transporters: Current and Future Perspectives (an ITC Sponsored Symposium) Co-Chairs: Donald Tweedie, Boehringer Ingelheim, Ridgefield, Connecticut, USA and Brian Houston, University of Manchester, Manchester, United Kingdom
16:00 – 16:30 | S18. APPLYING THE EU DDI RECOMMENDATIONS ON TRANSPORTERS – MPA EXPERIENCES AND FUTURE EXPECTATIONS Eva Gil Berglund, Medical Products Agency, Uppsala, Sweden
16:30 – 17:00 | S19. SUBSTRATE/INHIBITION ASSAYS AND PREDICTION OF DDIs Christoph Funk, F. Hoffmann-La Roche Ltd., Basel, Switzerland
17:00 – 17:30 | S20. PREDICTIONS OF CELLULAR DRUG BINDING AND IMPLICATIONS FOR INTRACELLULAR DRUG CONCENTRATIONS AND EFFECTS Par Matsson, Uppsala University, Uppsala, Sweden
17:30 – 18:00 | S21. N1-METHYLNICOTINAMIDE: AN ENDOGENOUS PROBE FOR DRUG INTERACTIONS BY RENAL CATION TRANSPORTERS? Martin Fromm, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
18:00 – 18:30 | POST-SYMPOSIUM DISCUSSION: ITC, CURRENT STATUS AND FUTURE DIRECTIONS Donald Tweedie, Boehringer Ingelheim, Ridgefield, Connecticut, USA
16:00 – 18:00 | AUDITORIUM B/C Parallel Symposium 6: Advances in Pathways of Chemically-induced Oxidative Stress and DNA Damage Co-Chairs: John Hayes, University of Dundee, Dundee, United Kingdom and Ken Tew, Medical University of South Carolina, Charleston, South Carolina, USA
16:00 – 16:30 | S22. CONTROL OF REDOX HOMEOSTASIS BY THE NRF2 REGULATORY NETWORK John Hayes, University of Dundee, Dundee, United Kingdom
16:30 – 17:00 | S23. REGULATION OF PROTEIN FUNCTION FOLLOWING S-GLUTATHIONYLATION Ken Tew, Medical University of South Carolina, Charleston, South Carolina, USA
17:00 – 17:30 | S24. THE REDOX CHEMISTRY OF ANTIOXIDANTS Claus Jacob, University of Saarland, Saarland, Germany
17:30 – 18:00 | S25. CONTROL OF H2O2 TRANSPORT IN AND BETWEEN CELLS Roberto Sitia, Division of Genetics and Cell Biology, Milan, Italy
18:30 – 19:30 | GLASGOW CITY CHAMBERS Civic Reception This is a ticketed event. See map on page 9 for directions.
19:30 – 22:00 | WAXY O’CONNOR’S New Investigators Networking Reception This event is open to students and new investigators. See map on page 9 for directions.
20:00 – 22:00 | THE CORINTHIAN CLUB ISSX President’s Reception By invitation.
Wednesday, June 24, 2015 08:00 – 17:00 | LEVEL 2 FOYER Meeting Registration Open
09:00 – 12:00| AUDITORIUM A Parallel Symposium 7: Humanised Animal Models in Drug Development Co-Chairs: Colin Henderson, University of Dundee, Dundee, United Kingdom and Frank Gonzalez, National Cancer Institute, Bethesda, Maryland, USA
09:00 – 09:30 | S26. HUMANISED MOUSE MODELS OF DRUG METABOLISM Colin Henderson, University of Dundee, Dundee, United Kingdom
09:30 – 10:00 | S27. MOUSE MODELS FOR ELUCIDATION OF CYP2D6 AND CYP2C19 FUNCTION IN THE DEVELOPING AND ADULT BRAIN Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden
10:00 – 10:30 | S28. KNOCKOUT AND HUMANISED MOUSE MODELS FOR DETOXIFYING PROTEINS Alfred Schinkel, The Netherlands Cancer Institute, Amsterdam, The Netherlands
10:30 – 11:00 | Refreshment Break
12
Scientific Program 11:00 – 11:30 | S29. LIPOPROTEIN AND BILE ACID PROFILES IN FRG MICE WITH HUMANISED LIVERS Ewa Ellis, Karolinska Institutet, Stockholm, Sweden
11:30 – 11:45 | P131. A PHARMACOKINETIC MODELING APPROACH TO PREDICT THE CONTRIBUTION OF ACTIVE METABOLITES TO HUMAN EFFICACIOUS DOSE Iain Martin, Merck, Boston, Massachusetts, USA
11:45 – 12:00 | P136. OPTIONS TO BOOST EXPOSURE OF ‘PROOF OF CONCEPT’ TOOL COMPOUNDS IN RODENTS TO ACCELERATE EARLY STAGE RESEARCH Lesley Murray, Genentech Inc., South San Francisco, California, USA
09:00 – 12:00 | AUDITORIUM B/C Parallel Symposium 8: The Contribution of the Gut Microbiome to Drug Metabolism, Drug Interactions and Drug Toxicity Co-Chairs: Heather Wallace, University of Aberdeen, Aberdeen, United Kingdom and Elaine Holmes, Imperial College London, London, United Kingdom
09:00 – 09:30 | S30. MICROBIOME METABOLOMICS Elaine Holmes, Imperial College London, London, United Kingdom
09:30 – 10:00 | S31. IMPACT OF HOST-MICROBIAL INTERACTIONS ON TOXICOKINETICS OF TACRINE Eric Chan, National University of Singapore, Singapore
10:00 – 10:30 | S32. REGULATION OF HOST METABOLISM BY THE GUT MICROBIOME THROUGH THE ARYL-HYDROCARBON-RECEPTOR Sven Pettersson, Karolinska Institutet, Stockholm, Sweden and Nanyang Technological University, Singapore
10:30 – 11:00 | Refreshment Break
11:00 – 11:30 | S33. THE IMPACT OF THE METAEXOMETABOLOME ON GUT FUNCTION AND HEALTH – A CASE STUDY OF SHORT CHAIN FATTY ACIDS Bernard Corfe, University of Sheffield, Sheffield, United Kingdom
11:30 – 11:45 | P40. ON-LINE ELECTROCHEMISTRY/MASS SPECTROMETRY (EC/MS) – A POWERFUL TOOL FOR THE PREDICTION OF DRUG OXIDATIVE METABOLISM REACTIONS AND THEIR MOLECULAR MECHANISM Agnieszka Potęga, Gdańsk University of Technology, Gdańsk, Poland
11:45 – 12:00 | P69. IN VITRO ASSESSMENT OF SKIN METABOLISM: COMPARISON OF METHODS AND IMPLICATIONS FOR WIDER APPLICATION Katie Plant, Cyprotex, Macclesfield, United Kingdom
12:00 – 13:30 | LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch
12:00 – 13:00 | LEVEL 2 FOYER Postdoctoral Poster Finalist Poster Presentations A7 – A12 Poster Presentations
12:30 – 13:30 | LEVEL 3 FOYER and ROOM 4/5 Poster Session 2: In silico – Transporters
P86 – P166 Poster Presentations
12:30 – 13:00 | Odd Numbered Posters
13:00 – 13:30 | Even Numbered Posters
13:30 – 15:30 | AUDITORIUM A Parallel Symposium 9: Epigenomics in Drug Metabolism and Disease Co-Chairs: Richard Meehan, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom and Jonathan Moggs, Novartis, Basel, Switzerland
13:30 – 14:00 | S34. EPIGENOMICS – IMPACT FOR TRANSLATIONAL SCIENCES Remi Terranova, Novartis, Basel, Switzerland
14:00 – 14:30 | S35. 5hmC – TISSUE SPECIFICITY AND MODULATION BY XENOBIOTICS John Thomson, University of Edinburgh, Edinburgh, United Kingdom
14:30 – 15:00 | S36. GENETIC-EPIGENETIC INTERACTIONS AND IMPLICATIONS FOR GENOME STABILITY/FUNCTION Thomas Carell, Ludwig Maximilian University of Munich, Munich, Germany
15:00 – 15:30 | S37. SPATIAL ORGANIZATION OF THE NUCLEUS AND INFLUENCE ON HUMAN DISEASE Wendy Bickmore, MRC Human Genetics Unit, University of Edinburgh, Edinburgh, United Kingdom
13:30 – 15:30 | AUDITORIUM B/C Parallel Symposium 10: Proteins as Targets for Covalent Modification by Xenobiotics: Therapeutic Opportunities versus Toxicological Risk Co-Chairs: Thomas Baillie, University of Washington, Seattle, Washington, USA and Kevin Park, University of Liverpool, Liverpool, United Kingdom
13:30 – 14:00 | S38. PHARMACOLOGICAL, PHYSIOLOGICAL, AND PATHOLOGICAL CONSEQUENCES OF DRUG BIOACTIVATION AND COVALENT BINDING Kevin Park, University of Liverpool, Liverpool, United Kingdom
14:00 – 14:30 | S39. REACTIVE DRUG METABOLITES AND TARGETED COVALENT INHIBITORS: A RISK-BENEFIT PERSPECTIVE Thomas Baillie, University of Washington, Seattle, Washington, USA
14:30 – 15:00 | S40. (DMPK) CHALLENGES IN DEVELOPING AZD9291: AN IRREVERSIBLE INHIBITOR OF EGFR SELECTIVE FOR SENSITISING AND T790M RESISTANCE MUTATIONS Peter Ballard, AstraZeneca, Cheshire, United Kingdom
15:00 – 15:30 | S41. INHIBITORS OF CATHEPSIN C: NOT YOUR TYPICAL ORAL SMALL MOLECULES Catherine Booth-Genthe, GlaxoSmithKline, Collegeville, Pennsylvania, USA
15:30 – 16:15 | LEVELS 2 and 3 FOYER Beverage Break / Meet Exhibitors / View Posters
16:15 – 17:30 | AUDITORIUM A/B/C Presentation of ISSX Awards and Award Lectures
16:15 – 16:55 | European Scientific Achievement Award James Brian Houston, PhD
16:55 – 17:30 | European New Investigator Award in Honor of Karl J. Netter Daniel J. Antoine, PhD
13
Scientific Program 18:30 – 22:00 | OLD FRUITMARKET Meeting Dinner and Ceilidh This is a ticketed event; tickets may be available for purchase at the registration desk. See map on page 18 for directions.
Thursday, June 25, 2015 08:00 – 17:00 | LEVEL 2 FOYER Meeting Registration Open
09:00 – 11:30 | AUDITORIUM A Parallel Symposium 11: Predicting Human Responses During Drug Discovery and Development Co-Chairs: Roland Wolf, University of Dundee, Dundee, United Kingdom and Peter Moldeus, Karolinska Institutet, Stockholm, Sweden
09:00 – 09:30 | S42. APPLICATION OF IN VIVO REPORTERS FOR STRESS RESPONSES IN DRUG DEVELOPMENT Roland Wolf, University of Dundee, Dundee, United Kingdom
09:30 – 10:00 | S43. PREDICTING HUMAN RESPONSES TO DRUGS: CHALLENGES AND OPPORTUNITIES OF IN VITRO APPROACHES Ruth Roberts, AstraZeneca, Wilmslow, United Kingdom
10:00 – 10:30 | S44. ESTABLISHING POTENTIAL SAFETY LIABILITIES IN EARLY DRUG DEVELOPMENT Bill Pennie, Takeda, Cambridge, Massachusetts, USA
10:30 – 11:00 | S45. THE APPLICATION OF EPIGENOME AND KINOME-BASED BIOASSAYS FOR RISK ASSESSMENT Ivonne Rietjens, Wageningen University, Wageningen, The Netherlands
11:00 – 11:15 | P29. APPLICATION OF A MOUSE LINE HUMANISED FOR HPXR/CAR/CYP3A4/CYP3A7/CYP2D6/CYP2C9 TO INVESTIGATE THE REVERSIBLE AND TIME-DEPENDENT INHIBITION OF MIDAZOLAM 1’-HYDROXYLATION Yury Kapelyukh, University of Dundee, Dundee, United Kingdom
11:15 – 11:30 | P82. HUMAN PLURIPOTENT STEM CELL-DERIVED HEPATOCYTES WITH SUBSTANTIAL METABOLIC FUNCTIONALITY AND ADULT CHARACTERISTICS ARE HIGHLY SUITABLE FOR TOXICITY TESTING Barbara Küppers-Munther, Takara Bio Europe (former Cellartis), Göteborg, Sweden
09:00 – 11:30 | AUDITORIUM B/C Parallel Symposium 12: Conjugating Enzymes and Hydrolases in Endogenous and Foreign Compound Metabolism Co-Chairs: Michael Arand, University of Zurich, Zurich, Switzerland and John Miners, Flinders University, Adelaide, Australia
09:00 – 09:30 | S46. A HYPERACTIVE mEH VARIANT: SEVERE TRADE-OFF FOR FASTER DETOX Anne Marowsky, University of Zurich, Zurich, Switzerland
09:30 – 10:00 | S47. DDIs INVOLVING GLUCURONIDATED DRUGS John Miners, Flinders University, Adelaide, Australia
10:00 – 10:30 | S48. ROLE OF SULTs IN METABOLIC ACTIVATION Hansruedi Glatt, German Institute of Human Nutrition, Berlin, Germany
10:30 – 11:00 | S49. CARBOXYLESTERASE 1 – SUBSTRATES, REGULATION OF ENZYME ACTIVITY AND PHARMACOGENETICS Henrik Rasmussen, Institute of Biological Psychiatry, Roskilde, Denmark
11:00 – 11:15 | P77. REGULATION OF UDP GLUCURONOSYLTRANSFERASE 2B15 AND 2B17 EXPRESSION BY MICRO-RNAS IN PROSTATE CELLS Peter Mackenzie, Flinders University, Adelaide, Australia
11:15 – 11:30 | P17. A NOVEL APPROACH IN MEASURING PROTEIN S-GLUTATHIONYLATION IN STRESS RESPONSE SIGNALLING David McGarry, University of Dundee, Dundee, United Kingdom
11:30 – 12:30 | LEVELS 2 and 3 FOYER Meet with Exhibitors / Lunch
12:30 – 13:00 | AUDITORIUM A/B/C Presentation of ISSX Poster Awards
13:00 – 15:00 | AUDITORIUM A/B/C Plenary Session: Inflammation: Effects on Drug Metabolism and Disease Aetiology Co-Chairs: Kathie Knights, Flinders University, Adelaide, Australia and Eddie Morgan, Emory University, Atlanta, Georgia, USA
13:00 – 13:30 | S50. INFLAMMATORY REGULATION OF HUMAN DRUG METABOLIZING ENZYMES Ulrich Zanger, Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany
13:30 – 14:00 | S51. REGULATION OF DRUG TRANSPORTERS IN INFLAMMATION: IMPACT ON DRUG DISPOSITION Micheline Piquette-Miller, University of Toronto, Toronto, Ontario, Canada
14:00 – 14:30 | S52. ROLE OF NO IN INFLAMMATORY REGULATION OF DRUG METABOLIZING ENZYMES Eddie Morgan, Emory University, Atlanta, Georgia, USA
14:30 – 15:00 | S53. INFLAMMATION AND LIVER DISEASE Percy Knolle, Technische Universität München, München, Germany
15:00 – 15:45 | AUDITORIUM A/B/C Closing Plenary Lecture Frank Gonzalez, National Cancer Institute, Bethesda, Maryland, USA
15:45 – 16:00 | AUDITORIUM A/B/C Closing Remarks Meeting Co-Chairs: Ann Daly and Roland Wolf
John Miners, President, International Society for the Study of Xenobiotics
Jae-Gook Shin, 11th
International ISSX Meeting Chair
Uwe Fuhr, 14th
European ISSX Meeting Chair
14
Poster Information
Poster Awards Competition Poster Presentations | LEVEL 2 FOYER
Poster
Session
Poster
Set-Up
Poster
Tear-Down*
Poster
Presentation
Dates and Times
Poster Awards
Presentation
Graduate / Predoctoral
Posters A1 – A6 LEVEL 2 FOYER
Tuesday, June 23
07:30 – 09:00
LEVEL 2 FOYER
Thursday, June 25
13:00 – 14:00
LEVEL 2 FOYER
Tuesday, June 23
12:00 – 13:00
AUDITORIUM
A/B/C
Thursday, June 25
12:30 – 13:00 Postdoctoral
Posters A7 – A12
LEVEL 2 FOYER
Wednesday, June 24
12:00 – 13:00
*All posters must be removed by 14:00 on Thursday, June 25. ISSX is not responsible for posters remaining after 14:00.
General Poster Abstracts Presentations | LEVEL 3 FOYER and ROOM 4/5
Poster
Session
Poster
Set-Up
Poster
Tear-Down**
Poster Presentation
Dates and Times
Session 1
Analytical – Hepatocytes Posters P1 – P85
LEVEL 3 FOYER
and ROOM 4/5
Tuesday, June 23
07:30 – 09:00
LEVEL 3 FOYER
and ROOM 4/5
Thursday, June 25
12:00 – 13:00
LEVEL 3 FOYER and ROOM 4/5
Tuesday, June 23
12:30 – 13:00 | Odd Numbered Posters
13:00 – 13:30 | Even Numbered Posters
Session 2
In silico – Transporters Posters P86 – P166
LEVEL 3 FOYER and ROOM 4/5
Wednesday, June 24
12:30 – 13:00 | Odd Numbered Posters
13:00 – 13:30 | Even Numbered Posters
**All posters must be removed by 13:00 on Thursday, June 25. ISSX is not responsible for posters remaining after 13:00.
View the poster numbering scheme on the following page.
15
Poster Information
Poster Number Quick Reference Guide:
Finalists in the Graduate / Pre-doctoral Poster Awards Competition A1 – A6
Finalists in the Postdoctoral Poster Awards Competition A7 – A12
Absorption P1 – P2
Analytical P3 – P6
Bioavailability P7 – P9
Clearance Prediction P10 – P16
Conjugation Reactions and Enzymes P17 – P19
Cytochrome P450 P20 – P28
Differences in Metabolism (species, gender, age, diseases) P29 – P32
Disposition P33 – P38
Drug Discovery and Development P39 – P42
Drug Interaction P43 – P58
Enzyme Induction P59 – P63
Enzyme Inhibition/Inactivation P64 – P68
Extrahepatic Metabolism P69
Gene Expression and Regulation P70 – P79
Genomics / Metabolomics / Proteomics P80 – P81
Hepatocytes P82 – P85
In silico P86 – P89
In vitro Techniques P90 – P93
Mechanisms of Xenobiotic Toxicities P94 – P105
Metabolic Profiling P106 – P111
Metabolism P112 – P120
Non-P450 Phase I Enzymes P121 – P122
Pharmacogenetics P123 – P130
Pharmacokinetics and Pharmacodynamics P131 – P140
Receptors / Nuclear Receptors P141 – P145
Transporters P146 – P166
Submit an Abstract for the 20th North American ISSX Meeting
We encourage all those involved in the fields of metabolism, pharmacology, toxicology, molecular biology and other related disciplines to consider submitting an abstract for a poster presentation at the 20th North American ISSX Meeting.
This meeting will provide a wonderful opportunity to showcase work being done in a variety of areas and to network with other researchers.
Abstract authors will have an opportunity to submit abstracts to the general abstract poster sessions and student authors can compete in the poster awards competition open to graduate/predoctoral and postdoctoral students. The call for abstracts closes Friday, July 10, 2015.
Visit www.issx.org/20na/abstracts to review the guidelines and submit your work.
16
Industry-Sponsored Symposium Industry-Sponsored Symposia (ISS) are commercially-supported educational sessions held in conjunction with the 13th European ISSX Meeting. This session has been approved for presentation at our meeting. All attendees are invited to enjoy a light breakfast and the education this session provides.
Tuesday, June 23, 2015
07:45 – 08:45 | AUDITORIUM A Presented by Quotient Bioresearch, Ltd. Biopharmaceuticals: Natural Products or Xenobiotic, Friend or Foe? Andrew McEwen, Chief Scientist, Quotient Bioresearch, Ltd.
Biopharmaceuticals (biologics) are broadly defined as medicinal products manufactured in, extracted from, or semi-synthesised from biological sources. They are seen as different from traditional pharmaceutical products (small molecules) and whilst there is a requirement to undertake laboratory and animal testing before they can be administered to man, such studies necessitate a science based, case-by case evaluation.
Regulatory guidelines, notably ICH S6 refer to the difficulty of providing a standard guidance for PK and TK studies for biologics, whilst noting the potential utility of both single and repeat dose PK studies along with tissue distribution studies. Classical biotransformation investigations as required for small molecules are considered unnecessary due to well understood catabolism to natural products, mainly amino acids, and there is no requirement to determine a mass balance to elicit excretion pathways. It has also been reported that current analytical methods have a limited capacity to separate and identify catabolites, and that even if formed these catabolites would have limited pharmacological or toxicological activity.
13th European ISSX Meeting Sponsor
ISSX thanks Solvo Biotechnology for their sponsorship of this meeting.
ISSX Corporate Partners
ISSX thanks these corporate sponsors for their support of ISSX this year.
17
Join fellow attendees for a delicious dinner and dance in a unique venue that presents Glasgow’s
history and charm. Set to begin at 18:30 on Wednesday, June 24, this is the premier social event of
the meeting and no better place for attendees to catch up with old friends and make new
acquaintances. A separate registration fee of $145 applies. Tickets may still be available at the ISSX
registration counter in the Level 2 Foyer. Only blocks away from the Technology and Innovation
Centre, this event can’t be missed!
18
Exhibitor Directory The support of the many vendors participating in our meeting exhibition significantly helps ISSX to organize and host leading scientific meetings. Please visit and spend time with each exhibiting company to learn how their products and services can help you with your research.
BIOPREDIC International Booth 103
BIOPREDIC International provides to industrial and academic researchers human and animal tissues, cells, fractions and reagents such as high quality hepatocytes and other derivatives of the liver, skin products, blood products and other biological fluids and non- standard animal products. These reagents are used for in vitro tests in pharmaceutical, cosmetic and chemical industry. BIOPREDIC International holds a portfolio of patents and licenses on the human liver cell line HepaRG®.
BioreclamationIVT Booth 101
BioreclamationIVT is a worldwide provider of biological and in vitro products to pharmaceutical and biotechnology organizations. Our company specializes in control animal, normal human and disease state human biological matrices for use in drug discovery along with hepatocyte and microsome products used in the preclinical industry.
BioReliance Booth 200
BioReliance offers a wide portfolio of innovative products and specialized services for preclinical drug metabolism and safety testing. Using our expertise in functional genomics we have developed novel genetically-modified cell based assays and tools to increase predictability and improve drug development success.
Corning Booth 502
Corning Incorporated offers integrated solutions to support life sciences and accelerate drug discovery with products and Contract Research Services for the in vitro analysis of xenobiotic metabolism and drug transport. Products include Corning® Gentest™ Hepatocytes, Tissue Fractions, Transporter Systems, Corning Supersomes™ Enzymes, and Corning Gentest Contract Research Services.
Covance Booth 104
Covance Inc., the drug development business of Laboratory Corporation of America® Holdings (LabCorp®) headquartered in Princeton, New Jersey, is the world's most comprehensive drug development company, dedicated to advancing healthcare and delivering Solutions Made Real®. Information on Covance's solutions can be obtained through its website at www.covance.com.
Cypex Booth 604
Cypex manufactures high quality recombinant CYPs from a range of species along with other enzymes such as AOX, ALDH, GSTs and SULTs as well as offering antibodies, purified CYPs, substrates and inhibitors. Services include CYP inhibition screening, protein expression and metabolite generation. Products and services are covered by an ISO9001:2008 accredited quality assurance system.
19
Exhibitor Directory
Cyprotex Discovery Ltd Booth 105
Cyprotex was founded in 1999 and has 100+ scientists specialising in in vitro and in silico ADME-Tox. Cyprotex performs both screening and regulatory (metabolite profiling, transporters, enzyme interactions etc.) work, and prides itself on our proprietary ADME-Tox technologies and added value (planning, interpretation) returned to customers through scientist-to-scientist communication.
Eurofins Pharma Discovery Services Booth 304
For over 40 years, Eurofins Pharma Discovery Services has been a trusted CRO supporting drug discovery from HTS to preclinical stages. Uniting the expertise of Cerep, Panlabs & Discovery Services, we support efficacy, safety & PK testing with our products and in vitro pharmacology, phenotypic, ADME-Tox and in vivo services.
HTG Molecular Diagnostics Booth 202
Headquartered in Tucson, Arizona, HTG Molecular Diagnostics’ mission is to provide simple, cost effective solutions for accurate RNA testing. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG Edge system capabilities have been expanded to fully automate sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Huntingdon Life Sciences/Harlan Laboratories Booth 306
Huntingdon Life Sciences/ Harlan Laboratories is an international CRO offering a comprehensive range of development services to pharmaceutical and biopharmaceutical companies. We help our customers develop safe and effective new compounds. Our Research Models and Services operating group provides high-quality research models and lab animal diets with support services worldwide.
Hurel Corporation Booth 503
HµREL® researches, develops, and commercializes products and services based on its patent-pending cell-based tissue constructs. Currently, Hurel offers primary hepatic co-culture models of the human, non-human primate, dog and rat species in almost any format; Hurel recently introduced a suite of services featuring Hurel’s robust co-culture platform. HurelTox™ multi-parametric toxicity screening service and Hurelflux™ patent-pending direct method to measure biliary efflux transporters. The Company’s HµRELflow™ multi-tissue microfluidic platform is currently in beta-test stage.
Informa Healthcare Booth 302
Informa Healthcare publishes more than 180 peer-reviewed journals spanning the complete spectrum of drug discovery to clinical medicine – from bench to bedside and beyond. If you are looking to submit research, then we have a publication to match. As of 2015 Informa Healthcare is part of the Taylor & Francis Group. Visit www.informahealthcare.com for more information about our range of titles.
20
Exhibitor Directory
InSphero, Inc. Booth 204
InSphero is the leading provider of 3D InSight™ Microtissues and screening services to the pharmaceutical, cosmetics and chemical industry. Our assay-ready 3D InSight™ Liver Microtissues (human, rat, HepG2, dog, cyno, minipig) enable more biologically relevant & predictive in vitro compound assessment, including long-term, low-dose toxicity and assessment of transporter function.
Lablogic Systems Booth 106
LabLogic Systems is a worldwide market leader in the supply of LIMS and chromatography data systems to pharmaceutical, academic, nuclear medicine and contract research laboratories. Our products include Debra LIMS for radiolabelled metabolism studies, radiochromatography detectors and software for HPLC and TLC, liquid scintillation and gamma counters.
Lhasa Limited Booth 107
Educational charity and active research organisation with an enviable reputation for collaborative work within different industry sectors; Lhasa Limited is a developer of prediction software and chemical databases. Derek Nexus: Toxicity prediction; Meteor Nexus: Metabolic fate prediction; Sarah Nexus: Toxicity prediction; Vitic Nexus: Chemical database; Zeneth: Chemical degradation prediction
Optivia Biotechnology Booth 505
Optivia Biotechnology is a leader in transporter biology research and services. Providing an array of transporter assays and offering comprehensive databases and models to help in the discovery and development of drugs with improved safety and efficacy.
PRIMACYT Cell Culture Technology GmbH Booth 602
PRIMACYT is a manufacturer of primary human and animal cells, media and consumables for in vitro technologies. We offer fresh and cryopreserved liver cells from all relevant species in pharmacology and toxicology. We are GLP certified, act as a contract researcher and serve as reference laboratory for the European Union.
QPS, LLC Booth 601
QPS is a GLP/GCP-compliant CRO that supports discovery, preclinical, and clinical drug development. We provide quality services in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine, and Early & Late Phase Clinical Research to clients worldwide. Our 30+ regional laboratories, clinical facilities and offices are located in North America, Europe, India and Asia. For more information, visit http://www.qps.com.
Qualyst Transporter Solutions, LLC Booth 600
Qualyst Transporter Solutions is the world’s exclusive provider of hepatic drug transporter products and contract research services, utilizing the proprietary B-CLEAR® technology, that support drug discovery and development. Our integrated hepatic model can investigate: intracellular concentration, transporter uptake and efflux mechanisms of clearance, drug transporter interactions related to induction and inhibition, and hepatic-related toxicities such as cholestasis and hyperbilirubinemia.
21
Exhibitor Directory
Quotient Bioresearch Booth 300
Quotient Bioresearch is a leading global CRO providing early stage and specialist drug development services to clients worldwide. We provide tailored and integrated solutions for pharmaceutical, biotechnology and agrochemical clients, using state-of-the-art technologies underpinned by unparalleled scientific, medical, chemical and biological expertise. For additional information contact us at [email protected].
Simulations Plus, Inc. Booth 206
GastroPlus™ sets the standard for PBPK/PD modeling for different administration routes in humans and animals, plus population simulations and DDI capabilities. DDDPlus™ and MembranePlus™ offer simulations of in vitro dissolution and permeability experiments. The ADMET Design Suite™ mines compound libraries, designs new molecules, and virtually screens structures for >140 ADMET properties.
SOLVO Biotechnology Booth 504
Drug Transporter Services and Products from the Expert! SOLVO Biotechnology is the leading provider of transporter assays Worldwide, since 1999. With over 100 solutions, we support your in-house or outsourced projects with high quality products or services, including FDA-, EMA, PMDA-ready reports. Please visit our booth #504 and www.solvo.com!
tebu-bio Booth 102
tebu-bio supplies the most innovative range of Services & Reagents for Life Sciences throughout Europe. Customers enjoy local customer service and support through tebu-bio’s European network of 9 offices. Specialists are always on hand to offer expert advice on choosing and using the best products suited to your research projects.
XenoTech, LLC Booth 100
XenoTech, LLC is a global Contract Research Organization with unparalleled experience and proven expertise from discovery through clinical support, providing cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADMET and pharmacology, in vivo ADMET and QWBA, metabolite ID and production, bioanalytical services and consulting. Visit www.xenotechllc.com for more information.
22
Notes
23
Notes
24
Technology and Innovation Centre Floor Plan
LEVEL 2: Registration, Poster Awards Finalists Posters, Exhibits 100 – 306, Auditorium A
LEVEL 3: Poster Sessions 1 and 2, Exhibits 500 – 601, Auditorium B/C
The 20th North American ISSX Meeting will bring together individuals who are actively working
on drug/xenobiotic research in diverse fields including basic and clinical pharmacology and
therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal
chemistry, molecular and structural biology, and genetics.
Visit www.issx.org/20na to learn about this exciting meeting and register today.
An International ISSX Meeting is a meeting for the entire Society that offers a broad ranging
program to serve the interests of all its scientific and geographical constituencies. Busan is the
second largest city in Korea. Located in the Southern part of the Korean peninsula, Busan is
easily accessible directly from 10 countries and also via Seoul from all over the world.
Visit www.issxbusan2016.org to make plans for attending this meeting in 2016.
SAVE THE DATE